Kairos Pharma (KAPA) investor relations material

Executive summary

• Clinical-stage biopharma focused on immunotherapy and cell therapy for oncology, with no approved products or product sales to date.

• Net loss of $1,654,000 for Q1 2026, up from $1,262,000 in Q1 2025; accumulated deficit reached $15,916,000 as of March 31, 2026.

• Raised $385,000 gross ($367,000 net) via ATM equity offering in Q1 2026; cash and equivalents at $3,675,000 at quarter-end.

• Entered into a manufacturing agreement with Brammer Bio (Patheon) for Phase II clinical supply of ENV-105.

Financial highlights

• Revenue: $0 for Q1 2026 and Q1 2025.

• Research and development expenses: $684,000 in Q1 2026, up from $493,000 in Q1 2025, driven by Phase 2 prostate cancer trial.

• General and administrative expenses: $1,006,000 in Q1 2026, up from $773,000 in Q1 2025, mainly due to increased professional service fees.

• Interest income: $36,000 in Q1 2026, up from $4,000 in Q1 2025.

• Net cash used in operating activities: $1,036,000 in Q1 2026; net cash provided by financing activities: $220,000.

Outlook and guidance

• Expects continued significant operating losses and increased expenses as clinical programs advance.

• Current cash balance may not fund planned operations for the next 12 months; additional funding required.

• Ongoing efforts to raise capital through equity, debt, or strategic partnerships.